阿尔托神经科学
ANRO
21.94
-0.68
-3.01%
阿尔托神经科学
US · ANRO
#3301 按市值排名
上市于 2024
21.94
-0.68
-3.01%
实时 - 追踪5344个代码 - 心跳于335秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量增加了2家。
- 机构持股总比例下降了4.5个百分点。
机构持股
- 机构持股比例
- 86.59% -4.54pp
- 机构数量
- 139 +2
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Hedge Fund47.15%
Mutual Fund27.14%
VC/PE Fund11.01%
Individual/Insider2.51%
Public Company0.85%
Private Company0.15%
Insurance Company0.14%
Government Pension Fund0.10%
Other10.91%
主要股东 截至 2026-06-30
Alpha Wave Global, LP
9.45% · 3.71M 股
Commodore Capital LP
6.94% · 2.72M 股
EcoR1 Capital, LLC
5.69% · 2.23M 股
BlackRock
5.40% · 2.12M 股
Perceptive Advisors LLC
4.10% · 1.61M 股
Vanguard Capital Management, LLC
4.08% · 1.60M 股
Adage Capital Management, L.P.
4.08% · 1.60M 股
Sirenia Capital Management LP
3.65% · 1.43M 股
Spruce Street Capital LP
3.45% · 1.35M 股
Vivo Capital, LLC
3.08% · 1.21M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 40次买入 · 9次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Amit Etkin | Founder, Chairman of the Board, CEO & President | 2.13% |
| Nicholas Smith | Chief Financial Officer | 0.20% |
| Po Chen | Director | 0.12% |
| Gwill York | Independent Director | 0.06% |
| Andrew Dreyfus | Independent Director | -- |
| Andrew Miller | Director | -- |
| Husseini Manji | Non-Employee Independent Director | -- |
| Raymond Sanchez | Director | -- |
| Michael Hanley | Chief Operating Officer | -- |
| Christopher Cox | Independent Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-10-01 | Nicholas Smith | Chief Financial Officer | Derivative Exercise and Retained | +55,000 | $2.32 |
| 2026-09-29 | Nicholas Smith | Chief Financial Officer | Derivative Exercise and Sale | -134,886 | $2.35–26.87 |
| 2026-09-28 | Nicholas Smith | Chief Financial Officer | Intent to Sell (Form 144) | -134,886 | $26.66 |
| 2026-05-26 | Andrew Miller | Director | Other Derivative Acquisition | +26,000 | $20.44 |
| 2026-05-13 | Amit Etkin | Founder, Chairman of the Board, CEO & President | Other Disposition | -400,000 | -- |
| 2026-05-11 | Gwill York | Independent Director | Other Derivative Acquisition | +10,958 | $24.63 |
| 2026-05-11 | Andrew Dreyfus | Independent Director | Other Derivative Acquisition | +10,958 | $24.63 |
| 2026-05-11 | Husseini Manji | Non-Employee Independent Director | Other Derivative Acquisition | +10,958 | $24.63 |
| 2026-05-11 | Raymond Sanchez | Director | Other Derivative Acquisition | +10,958 | $24.63 |
| 2026-05-11 | Christopher Cox | Independent Director | Other Derivative Acquisition | +10,958 | $24.63 |
| 2026-02-28 | Nicholas Smith | Chief Financial Officer | Sale to Issuer | -2,806 | $19.69 |
| 2026-02-28 | Amit Etkin | Founder, Chairman of the Board, CEO & President | Sale to Issuer | -6,227 | $19.69 |
| 2026-02-10 | Nicholas Smith | Chief Financial Officer | Other Derivative Acquisition | +200,000 | $16.71 |
| 2026-02-10 | Amit Etkin | Founder, Chairman of the Board, CEO & President | Other Derivative Acquisition | +306,000 | $16.71 |
| 2026-02-10 | Michael Hanley | Chief Operating Officer | Other Derivative Acquisition | +131,000 | $16.71 |
| 2026-02-10 | Adam Savitz | Chief Medical Officer | Other Derivative Acquisition | +124,000 | $16.71 |
| 2026-01-01 | Gwill York | Independent Director | Other Derivative Acquisition | +5,243 | $16.59 |
| 2026-01-01 | Husseini Manji | Non-Employee Independent Director | Other Derivative Acquisition | +4,228 | $16.59 |
| 2026-01-01 | Raymond Sanchez | Director | Other Derivative Acquisition | +3,806 | $16.59 |
| 2026-01-01 | Christopher Cox | Independent Director | Other Derivative Acquisition | +7,189 | $16.59 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:05 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
阿尔托神经科学 讨论区 0 条评论